ClinicalTrials.gg
CompletedNCT02688270Updated Nov 2, 2022Results posted

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

A Phase 2 interventional study of Vascana (0.9% nitroglycerin cream) and Vehicle Cream (placebo) in Raynaud's Phenomenon Secondary to Connective Tissue Disease, sponsored by Covis Pharma S.à.r.l.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Covis Pharma S.à.r.l. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Connective Tissue Diseases with a site in United States — 17 open to participants now, 27 under way, 12 of them phase 3. Connective Tissue Diseases · United States.

Enrollment
35th of 68
65 · median 67
Started
2016
with 1 other
Phase 2
24 of 95
1 open now
Registered
53rd of 95
by date

Among the 95 studies in Connective Tissue Diseases with a site in United States, this one is the 35th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2016, is one of 24 in phase 2, and was the 53rd registered.

Connective Tissue Diseases

192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.

Browse Connective Tissue Diseases studies →

Open to participants now

17 of the 95 studies in Connective Tissue Diseases with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Connective Tissue Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.

03

Conditions studied

  • Raynaud's Phenomenon Secondary to Connective Tissue Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written consent prior to any study-specific evaluation
  2. Males and females aged 18 years to 75 years, inclusive
  3. A clinical diagnosis of secondary Raynaud's Phenomenon (defined as Raynaud's Phenomenon (RP) significant enough to cause a patient to modify daily behavior) as determined by a history of cold sensitivity with pain, numbness, and/or tingling along with pallor or cyanosis of the fingers, or by such an event observed by the study physician and a diagnosis of a disease state known to be associated with RP. Secondary RP may be due to scleroderma, systemic lupus erythematosus, mixed connective tissue disease, or other connective tissue diseases
  4. Agree to apply the study drug to their fingers as specified in the protocol
  5. Agree to the controlled cold exposures as described in the protocol
  6. Willing to discontinue current vasodilator therapies used specifically for the treatment of Raynaud's
  7. Agree not to use any other medications or approved or unapproved therapies to treat RP and its symptoms while participating in this study. Such medications include, but are not limited to: other dosages forms of nitroglycerin, eg, isosorbide dinitrate, fenoldopam mesylate, milrinone lactate, nifedipine, diltiazem, felodipine, nimodipine, nisoldipine, fluoxetine, pregabalin, and verapamil. Use of phosphodiesterase 5 inhibitors (eg, sildenafil, tadalafil, vardenafil) is excluded unless being used intermittently for male erectile dysfunction and not taken within 48 hours of scheduled study drug dosing
  8. Negative urine pregnancy test for women of prior to the first study treatment and who agree to use effective throughout the study
  9. Able to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  1. Past history of RP attacks of sufficient severity as to require inpatient hospitalization
  2. Presence of an active digital ulcer defined as a painful ulcer with visible depth and loss of epithelialization. Ulcers covered with eschar wherein depth and epithelialization cannot be judged are said to be "indeterminant" and are not exclusionary.
  3. Raynaud's Phenomenon secondary to non-connective tissue disorders including thromboangiitis obliterans (Buerger's disease), hemorheologic disorders, major arterial occlusive disease, past exposure to vasopathic agents (including vinblastine, cis platinum, and bleomycin), ongoing therapy with vasoconstrictive agents (eg, beta-blockers), and past frostbite injury amongst others. Subjects with should also be excluded.
  4. Patients diagnosed with pulmonary arterial hypertension requiring specific therapy.
  5. Concurrently using any nitrate medication or medications known to interact with nitroglycerin such as sildenafil, and other treatments for erectile dysfunction beyond screening. Subjects may participate in the study once these drugs have been discontinued for at least 5 half-lives
  6. Concurrently using any medication or device which might interfere with the study medication (including RP therapies, drugs used for hypertension, arrhythmia, depression, and pain), specifically calcium channel blockers and the compounds listed in prohibited concomitant medications beyond screening, unless such medication is required for a condition other than Raynaud's. Subjects may participate in the study once these drugs have been discontinued for at least 5 half-lives.
  7. Known allergy to nitroglycerin or common topical cream ingredients
  8. History of migraine, cluster, or vascular headaches, or chronic pain (defined as pain of 3-hour duration or longer on a daily basis) with greater intensity than the pain associated with RP or other chronic pain condition in their fingers
  9. Any unstable medical problem or any current medical condition that, in the judgment of the investigator, would contraindicate the administration of the study medication, interfere with the study evaluations, or interfere with the subject's ability to comply with the study protocol
  10. Cognitive or language difficulties that would impair completion of the symptom assessment instruments
  11. Within the past 3 months, have had a myocardial infarction, uncontrolled congestive heart failure, unstable angina, uncontrolled hypotension, or uncontrolled hypertension (defined as subjects not being treated medically to control these conditions)
  12. Participated in a study of any drug within 4 weeks prior to visit 1
  13. Screening laboratory values are 20% or more from the upper or lower limit of normal and that are considered to be to the investigator
  14. Had major abdominal, thoracic, or vascular surgery within 6 months of visit 1
  15. Pregnant or nursing women
  16. Women of who are unable or unwilling to comply with the requirements during the study period
  17. History of relevant drug and/or food allergies that resulted in a systemic reaction that required medical treatment
  18. History of alcohol abuse or drug addiction which in the estimation of the principal investigator would affect the subjects ability to participate in the study
  19. Consumption of alcohol on day before a visit and day of the visit.
  20. Consumption of two or more alcoholic beverages on a daily basis.
  21. Use of tobacco products of any type and at any level in the preceding 6 months and for the duration of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Treatment Sequence A

    Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream

    Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)

  • Experimental
    Treatment Sequence B

    Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vehicle cream, Vascana® (0.9% nitroglycerin cream)

    Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)

  • Experimental
    Treatment Sequence C

    Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream)

    Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)

  • Experimental
    Treatment Sequence D

    Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vascana® (0.9% nitroglycerin cream), Vehicle cream

    Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)

Interventions

06

What researchers measure

Primary outcomes

  1. Raynaud's Symptom Severity (Change From Baseline)

    Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom.

    Time frame: 6 weeks

  2. Raynaud's Symptom Severity (Percentage of Responders)

    Time frame: 6 weeks

07

Results

Posted Nov 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence ATreatment Sequence BTreatment Sequence CTreatment Sequence D
Started16161716
Completed16161716
Not completed0000

Outcome measures

PrimaryRaynaud's Symptom Severity (Change From Baseline)

Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom.

Time frame:
6 weeks
Reported as:
Least squares mean · score on a scale
Raynaud's Symptom Severity (Change From Baseline)
score on a scaleVascanaVehicle Cream
Raynaud's Symptom Severity (Change From Baseline)-20.19 (-26.63 to -13.75)-18.63 (-25.07 to -12.19)
PrimaryRaynaud's Symptom Severity (Percentage of Responders)
Time frame:
6 weeks
Reported as:
Count of participants · Participants
Raynaud's Symptom Severity (Percentage of Responders)
ParticipantsVascanaVehicle Cream
Raynaud's Symptom Severity (Percentage of Responders)3729

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vascana0/65 (0%)17/65 (26.2%)1/17 (5.9%)
Vehicle Cream0/65 (0%)16/65 (24.6%)3/16 (18.8%)
Most frequent serious events
Most frequent serious events
EventVascanaVehicle Cream
Blood Pressure IncreasedVascular disorders8/657/65
Nervous System DisordersNervous system disorders1/654/65
General disorders and administration site conditionsGeneral disorders3/651/65
HypertensionVascular disorders1/653/65
Infections and infestationsInfections and infestations2/651/65
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders2/650/65
Most frequent other events
Most frequent other events
EventVascanaVehicle Cream
Blood Pressure IncreasedVascular disorders1/172/16
HypertensionVascular disorders0/171/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Sequence ATreatment Sequence BTreatment Sequence CTreatment Sequence DTotal
Mean52.3 ± 13.3753.8 ± 11.4252.1 ± 16.2447.7 ± 13.3451.4 ± 13.61
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ATreatment Sequence BTreatment Sequence CTreatment Sequence DTotal
Female1415161560
Male21115
Region of Enrollment
Region of Enrollment(participants)Treatment Sequence ATreatment Sequence BTreatment Sequence CTreatment Sequence DTotal
United States1616171665
08

Study locations

1 site
  • Multiple investigational sites
    Multiple Locations, Pennsylvania, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2022, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Feb 23, 2016
Start
Jun 2016
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results first posted
Nov 2, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02688270
Lead sponsor
Covis Pharma S.à.r.l.
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
Jun 2016
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Nov 2, 2022
Last update
Nov 2, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion